In terms of sales, Pfizer is the biggest biopharmaceutical company in the world. In 2022, it will have made nearly $100 billion in sales.
It was the company’s best year ever, which is a big deal when you think about how hard it is for currencies around the world to stay stable. The biggest pharmaceutical company in the world has a big presence in the women’s health industry.
The company comes up with birth control pills and injections like Lybrel and Loestrin. Even though Pfizer broke records in 2022, the company might still be undervalued.
It trades at a forward price-to-earnings ratio of 11.34, which is less than the average of 14x for the sector. Pfizer does not qualify as a dividend aristocrat.
- Advertisement -
But since its payout has gone up for 12 years in a row, it may be on its way to becoming the best. Investors get a nice dividend yield of 3.83% from the company right now.
Shares of the company have been going down since November 2021, when they hit their all-time high. Which is in line with how the market is doing as a whole. Shareholders, on the other hand, only need to step back a bit to see that the overall uptrend that has been going on since 2008 is still going strong.